Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.
Protocol to generate traceable CAR T cells for syngeneic mouse cancer models.
复制标题
为同基因小鼠癌症模型生成可追踪 CAR T 细胞的方案。
DOI：
10.1016/j.xpro.2024.102898
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Fan,Yi
中科院分区：
文献类型：
--
作者：
Zhang,Duo;Krimitza,Elisavet;Han,Katherine;Su,Ruiying;Xu,DavidJ;Xu,JaidenR;Gong,Yanqing;Fan,Yi
嵌合抗原受体（CAR）T细胞免疫疗法的功效受到由于免疫抑制性肿瘤微环境导致的T细胞浸润和活化不足的限制。在免疫活性小鼠癌症模型中使用优化的小鼠CAR T细胞进行的临床前研究将有助于确定免疫治疗抗性的潜在机制。在这里，我们提出了一种制备小鼠T细胞和产生CAR T细胞的方案。然后，我们详细介绍了测试其治疗效果并在同基因小鼠胶质瘤模型中追踪它们的程序。关于本方案的使用和执行的完整细节，请参见Zhang et al.
The efficacy of chimeric antigen receptor (CAR) T cell immunotherapy is limited by insufficient infiltration and activation of T cells due to the immunosuppressive tumor microenvironment. Preclinical studies with optimized mouse CAR T cells in immunocompetent mouse cancer models will help define the mechanisms underlying immunotherapy resistance. Here, we present a protocol for preparing mouse T cells and generating CAR T cells. We then detail procedures for testing their therapeutic efficacy and tracking them in a syngeneic mouse glioma model.For complete details on the use and execution of this protocol, please refer to Zhang et al.1